큐라티스

348080KOSDAQ자연과학 및 공학 연구개발업

73.6 / 100

Reference Date: 2026-07-24

Financial Score28.0 / 40

News Sentiment15.6 / 25

Momentum20.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 443.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Curatis develops vaccines using its platform technology, including QTP101 (tuberculosis prevention), QTP105 (schistosomiasis prevention), and QTP104 (next-generation mRNA-based COVID-19 vaccine). QTP101 has received global Phase 2b/3 trial approval, and the company also provides CMO/CDMO services and open innovation solutions for drug development.

Number of Employees

47people

Average Salary

58.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

0.57Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE

-91.68Industry Average -32.093.5Point

2.9x industry avg (excellent)

Debt Ratio

0.06Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲246.8% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲15.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -92.3% (improving, 2yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 62.5

Neutral
큐라티스, 내달 1일부터 주권매매거래 정지
큐라티스의 주권매매거래가 일시 중단되나, 직접적인 시장 영향은 제한적임.
Positive
삼성바이오 "차세대 모달리티 연구 중…고객사 신약에 적용할 것"
큐라티스 관련 직접적인 영향은 없으나, 삼성바이오로직스의 혁신적인 모달리티 연구가 긍정적인 시장 분위기를 조성함.

Detailed Momentum

52-week position8.0Point

Near 52w high (93%, uptrend)

Current 1,962Won52-week high 2,08052-week low 309

1-month return6.0Point

1m +443.49% (strong rise)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주권매매거래정지해제 (감자 주권 변경상장)2026-07-16
Neutral감자완료2026-07-10
Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-06-26